Aslan doubles down on CSL drug, plots longshot rivalry with Dupixent in atopic dermatitis
When Aslan Pharmaceuticals licensed the anti-IL13 receptor drug ASLAN004 from CSL, the plan was to hustle it through early-stage development then pass it off to a third company for commercialization. But after seeing some proof-of-concept data, the Singaporean biotech has decided to keep the drug for itself instead.
In an amended deal, Aslan is pledging $30 million payable once it launches a Phase III. And CSL — which previously was entitled to about half of any licensing revenue — now stands to receive $95 million in regulatory milestones and $655 million more for future sales, plus royalties.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
